CompletedNot Applicable

Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone

France77 participantsStarted 2011-04

Plain-language summary

This study is conducted in Europe. The purpose of this study is to assess the impact on daily life for children new to using a growth hormone injection device.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Growth hormone (GH) treatment naïve subjects for whom it has been decided to initiate GH treatment prior to enrollment into the study * Subjects who receive Norditropin NordiFlex® according to the SPC Exclusion Criteria: * Known or suspected allergy to study product(s) or related products * Child and/or parent unable to give consent or fill out the questionnaires * The receipt of any investigational medicinal product within 3 months prior to this study * Suffer from a life-threatening disease

What they're measuring

Usability of growth hormone injection device assessed by a quantitative scale

Timeframe: after 3 months of growth hormone treatment

Trial details

NCT IDNCT01327924

SponsorNovo Nordisk A/S

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2012-06

View on ClinicalTrials.gov More Growth Hormone Disorder trials